A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company’s the operating results for 2017.
Immunogen is a clinical-stage biotechnology company developing targeted cancer therapeutics using the companies proprietary ADC technology. With it’s lead product candidate, mirvetuximab soravtansine (IMGN-853), in a Phase III clinical trials for FRα-positive platinum-resistant ovarian cancer, and a Phase Ib/II trial in combination regimens for earlier-stage disease as well as three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals, the company has seen significant progress and robust growth.
…we anticipate completing patient enrollment in our FORWARD I Phase III registration trial by mid-year 2018 and multiple data readouts from our FORWARD II trial assessing combinations with mirvetuximab soravtansine…
“We advanced our monotherapy registration study and published compelling combination data with mirvetuximab soravtansine, expanded our clinical pipeline, and established a high-value partnership with Jazz Pharmaceuticals supporting our earlier-stage programs,” noted Mark Enyedy, ImmunoGen’s president and chief executive officer.
“With the momentum we generated in the last twelve months… we anticipate completing patient enrollment in our FORWARD I Phase III registration trial by mid-year, multiple data readouts from our FORWARD II trial assessing combinations with mirvetuximab soravtansine beginning next month at the Society of Gynecologic Oncology annual meeting, and clinical data from our Phase I trials of both IMGN779 and IMGN632 later in the year. With these anticipated events, we look forward to another productive year in 2018 as we advance our pipeline to bring new therapies to patients and create value for our shareholders.”
In 2017 Immunogen activated more than 100 sites in North America and Europe in the Company’s ongoing Phase III FORWARD I trial of mirvetuximab soravtansine as single-agent therapy for platinum-resistant ovarian cancer enabling rapid patient enrollment. The company also advanced the its Phase Ib/II FORWARD II trial in North America and Europe evaluating mirvetuximab soravtansine combination regimens in separate expansion cohorts with pembrolizumab (Keytruda®; Merck Sharp & Dohme, a subsidiary of Merck & Co.) and bevacizumab (Avastin®; Genentech/Roche) for the treatment of patients with platinum-resistant disease, and initiated patient dosing in a new cohort to evaluate the triplet combination of mirvetuximab soravtansine + carboplatin and bevacizumab in patients with platinum-sensitive disease.
Reported updated safety data and preliminary anti-leukemia activity from the dose-escalation phase of the Phase I clinical trial of IMGN779 in patients with acute myeloid leukemia (AML) were reported at the American Society of Hematology (ASH) Annual Meeting held in December 2017 in Atlanta, Georgia.
Researchers also began dosing patients in the Immunogen’s Phase I clinical trial of IMGN632, a CD123-targeting ADC integrating a potent DNA-alkylating payload intended to treat a range of hematological malignancies, including AML and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Finally, Takeda, Immunogen’s development partner filed an IND for TAK-164, an ADC directed to GCC-positive tumors using ImmunoGen’s IGN platform.
Following an in-depth review of the company’s manufacturing strategy, ImmunoGen announced that it will move to a new operating model that will rely on external manufacturing and quality testing for drug substance and drug product for its development programs. The implementation of this new operating model will lead to the ramp-down of manufacturing and quality activities at the Company’s Norwood, Massachusetts facility by the end of 2018, with a full exit of the site by early 2019. Decommissioning the Norwood facility will result in anticipated cost savings of over $20 million during the next five years.
The Norwood facility has been a long-standing staple of ImmunoGen’s business, delivering high-quality products to patients and partners without interruption for more than 25 years. The Company is grateful for the contributions that its Norwood-based employees have made and will support these employees through the transition.
FORWARD I and II
In the first quarter of 2018, Immunogen is is expected to conduct a interim analysis from FORWARD I, for futility only, and report updated dose-escalation findings from the FORWARD II mirvetuximab soravtansine + pembrolizumab combination cohort at the Society of Gynecologic Oncology annual meeting in March 2018.
Further, during the annual meeting of the American Association for Cancer Research (AACR) in April, representatives of the company will highlight ImmunoGen’s technology and innovation in ADCs at (April 2018)
The company is also anticipating that its partner Takeda will begin clinical development of TAK-164 in the first half of 2018. TAK-164 is a fully human IgG1 monoclonal antibody directed towards the extracellular domain of guanylyl cyclase C (GCC) conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (also known as IGN-P1).
TAK-164 is the second ADC to target guanylyl cyclase, after Takeda discontinued TAK-264, also known as indusatumab vedotin. While indusatumab vedotin utilizes a MMAE payload, TAK-164 contains the DNA alkylating agent indolino-benzodiazepine.
Report updated data from the FORWARD II mirvetuximab soravtansine + bevacizumab combination expansion cohort in over 50 patients in the first half of 2018.
Immunogen also plans to complete patient enrollment in the FORWARD I clinical trial by by mid-2018, report findings from the FORWARD II mirvetuximab soravtansine + pembrolizumab combination expansion cohort in over 30 patients in the second half of the year, report additional data from IMGN779 Phase I study as well as initial data from IMGN632 Phase I in the last quarter of 2018 and advance the company’s ADAM9 program into IND-enabling activities before year-end.